Showing results (51-60 of 60) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Cancer Medicine|March 14, 2018
Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 studyXiaojun Huang, Lugui Qiu, Jie Jin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2021
Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTORHervé Avet-Loiseau, Jesus San-Miguel, Tineke Casneuf, et al.Lancet (London, England)|December 18, 2015
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 studyMartin Dreyling, Wojciech Jurczak, Mats Jerkeman, et al.HPB : the Official Journal of the International Hepato Pancreato Biliary Association|October 18, 2019
Hepatic angiomyolipoma: an international multicenter analysis on diagnosis, management and outcomeAnne J Klompenhouwer, Roy S Dwarkasing, Michael Doukas, et al.Journal of the American Chemical Society|December 26, 2025
Deciphering Ibogaine's Matrix Pharmacology: Multiple Transporter Modulation at Serotonin SynapsesChristopher Hwu, Václav Havel, Xavier Westergaard, et al.Leukemia & Lymphoma|August 9, 2020
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphomaGraeme A M Fraser, Asher Chanan-Khan, Fatih Demirkan, et al.Blood|July 16, 2021
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONEJesus San-Miguel, Hervé Avet-Loiseau, Bruno Paiva, et al.The Lancet. Oncology|December 15, 2015
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 studyAsher Chanan-Khan, Paula Cramer, Fatih Demirkan, et al.Blood|July 21, 2021
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIAMichele Cavo, Jesus San-Miguel, Saad Z Usmani, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2019
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell LymphomaAnas Younes, Laurie H Sehn, Peter Johnson, et al.Pageof 6